555 related articles for article (PubMed ID: 23142406)
21. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
22. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.
Tang LH; Gonen M; Hedvat C; Modlin IM; Klimstra DS
Am J Surg Pathol; 2012 Dec; 36(12):1761-70. PubMed ID: 23026928
[TBL] [Abstract][Full Text] [Related]
23. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
[TBL] [Abstract][Full Text] [Related]
24. Recent updates on grading and classification of neuroendocrine tumors.
Kim JY; Hong SM; Ro JY
Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
[TBL] [Abstract][Full Text] [Related]
25. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases.
Estrozi B; Bacchi CE
Clinics (Sao Paulo); 2011; 66(10):1671-5. PubMed ID: 22012036
[TBL] [Abstract][Full Text] [Related]
27. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
Fitzgerald TL; Mosquera C; Lea CS; McMullen M
Am Surg; 2017 Jul; 83(7):799-803. PubMed ID: 28738955
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
29. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
31. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
32. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
[TBL] [Abstract][Full Text] [Related]
33. [Gastroenteropancreatic neuroendocrine tumors: clinical characteristics, diagnosis and prognosis at Hospital Universitario Clínico San Carlos (Madrid)].
de Miguel Novoa MP; Fernández Capel F; Redondo Sedano JV; Sellers Carrera M; Aranda Jiménez V; Ortiz Pereira P; Sastre Valera J; Ortega Medina L; Díaz Pérez JÁ
Endocrinol Nutr; 2014 May; 61(5):234-41. PubMed ID: 24560439
[TBL] [Abstract][Full Text] [Related]
34. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
35. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
[TBL] [Abstract][Full Text] [Related]
36. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
37. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
[TBL] [Abstract][Full Text] [Related]
38. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
Garcia-Carbonero R
Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
[No Abstract] [Full Text] [Related]
39. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.
Mejia A; Vivian E; Nwogu C; Shah J; Longoria R; Vo A; Shahin I; Verma J; Bageac A
Medicine (Baltimore); 2022 Mar; 101(9):e28970. PubMed ID: 35244064
[TBL] [Abstract][Full Text] [Related]
40. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
